树突状细胞经MHC cross-dressing诱导CD8+T细胞靶向杀伤三阴性乳腺癌的机制研究

三阴性乳腺癌（TNBC）的现有治疗方法较为有限且疗效不佳，免疫疗法是TNBC的潜在治疗手段。树突状细胞（DC）疫苗是免疫疗法的重要一种，尤其是DC介导的MHC cross-dressing抗原递呈方式具有潜在的应用价值。然而，该抗原递呈方式对TNBC是否适用，目前尚未知。我们前期发现TNBC细胞可与DC发生MHC cross-dressing，而且还发现一种miRNA(miR-4494)可能参与调控该过程。因此，本课题拟深入研究DC对TNBC MHC cross-dressing的作用以及对抗原特异性CD8+T细胞的免疫效应，在聚焦DC发生MHC cross-dressing的机制上，研究miR-4494对MHC cross-dressing的分子调控机制。通过对本课题的研究，将有助于阐明MHC cross-dressing的分子机制，为制备DC疫苗以用于TNBC的免疫治疗提供理论依据。

Immunotherapy is a potential treatment for triple-negative breast cancer (TNBC). Dendritic cell (DC) vaccine is an important immunotherapy, especially DC mediated MHC cross-dressing antigen presentation has potential application value. However, it is not known whether this application is suitable for TNBC. We have found that TNBC antigen peptide and MHC class I complex could develop MHC cross-dressing with DC, and a miRNA (mir-4494) may participate in this process. We intend to further explore the anti-tumor effect of DC on TNBC MHC cross-dressing as well as the activation of antigen-specific CD8+T cells, and study the mechanism of mir-4494 on MHC cross-dressing by focusing on the regulatory molecular mechanism. This project will help us to elucidate the molecular mechanism of MHC cross-dressing and provide theoretical basis for the treatment of TNBC in future.